Traders Purchase High Volume of Call Options on Immunic (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) saw some unusual options trading activity on Tuesday. Traders purchased 2,229 call options on the company. This represents an increase of 849% compared to the typical daily volume of 235 call options.

Wall Street Analyst Weigh In

Several research analysts recently commented on IMUX shares. William Blair started coverage on shares of Immunic in a report on Tuesday. They set an “outperform” rating for the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Immunic in a research note on Friday, February 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Immunic in a research report on Wednesday, February 26th. Finally, StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $12.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC lifted its holdings in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. HB Wealth Management LLC bought a new position in shares of Immunic in the fourth quarter valued at about $81,000. State Street Corp lifted its stake in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Immunic during the 3rd quarter worth about $50,000. 51.82% of the stock is currently owned by institutional investors.

Immunic Stock Performance

Immunic stock opened at $1.20 on Thursday. The stock has a 50-day simple moving average of $1.07 and a 200 day simple moving average of $1.21. The stock has a market capitalization of $108.09 million, a P/E ratio of -0.98 and a beta of 1.89. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.